Aptevo Therapeutics Inc (APVO) Stock Price, Quote & News

Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 838 0500

Fax: 206 838 0503

Website: aptevotherapeutics.com

Address:

2401 4th Avenue, Suite 1050, Seattle, United States

BLOCKS77 Apr. 6 at 7:34 PM

$APVO

0 · Reply

ProfessorDman1 Apr. 2 at 2:37 PM

$APVO 100%-500% range still active here We saw what happened to $ELAB another bio low floater 1-14 run 600%+ 🤓

0 · Reply

Habib1234 Apr. 1 at 8:21 AM

$APVO

0 · Reply

MrDaniels Apr. 1 at 7:11 AM

$APVO 👀…whatcha doin’?

0 · Reply

azazelhazel Apr. 1 at 1:22 AM

$APVO

0 · Reply

ProfessorDman1 Mar. 31 at 11:41 PM

$APVO holding full going into tomorrow

0 · Reply

alert716 Mar. 31 at 11:33 PM

$ELAB Real free daily Alerts!! 🤑🤑🤑 $APVO $MASK $GV $INDO

0 · Reply

MrDaniels Mar. 31 at 11:01 PM

$APVO wen $10?

1 · Reply

ProfessorDman1 Mar. 31 at 10:16 PM

$APVO $20+ could happen multi day

0 · Reply

Habib1234 Mar. 31 at 10:09 PM

$APVO

0 · Reply

Aptevo Provides State of the Business Report and 2025 Financial Results

Mar 19, 2026, 8:05 AM EDT - 18 days ago

Aptevo to Participate in March 2026 Conferences

Mar 10, 2026, 8:05 AM EDT - 27 days ago

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Feb 3, 2026, 8:05 AM EST - 2 months ago

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Jan 9, 2026, 8:05 AM EST - 3 months ago

Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

Dec 26, 2025, 8:05 AM EST - 3 months ago

Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

Dec 9, 2025, 8:05 AM EST - 4 months ago

Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

Nov 10, 2025, 8:05 AM EST - 5 months ago

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

Nov 6, 2025, 8:05 AM EST - 5 months ago

Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update

Oct 8, 2025, 8:20 AM EDT - 6 months ago

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

Sep 16, 2025, 8:30 AM EDT - 7 months ago

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

Sep 4, 2025, 8:45 AM EDT - 7 months ago

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Aug 13, 2025, 8:05 AM EDT - 8 months ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aug 11, 2025, 8:05 AM EDT - 8 months ago

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Jun 20, 2025, 11:30 AM EDT - 10 months ago

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2025, 8:55 AM EDT - 10 months ago

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Jun 20, 2025, 8:01 AM EDT - 10 months ago

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

SWBI

Jun 18, 2025, 1:34 PM EDT - 10 months ago

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Jun 18, 2025, 11:37 AM EDT - 10 months ago

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Jun 18, 2025, 10:52 AM EDT - 10 months ago

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2025, 8:01 AM EDT - 10 months ago

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Jun 13, 2025, 8:05 AM EDT - 10 months ago

Aptevo Participating in the BIO International Convention

May 22, 2025, 8:05 AM EDT - 11 months ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 15, 2025, 8:05 AM EDT - 11 months ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 8, 2025, 8:45 AM EDT - 11 months ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 21, 2025, 2:40 PM EDT - 1 year ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 4, 2025, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 3, 2025, 8:50 AM EDT - 1 year ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 20, 2025, 8:35 AM EDT - 1 year ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Mar 18, 2025, 8:05 AM EDT - 1 year ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Mar 6, 2025, 8:00 AM EST - 1 year ago

Aptevo to Participate in March Conferences

Feb 15, 2025, 6:59 PM EST - 1 year ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 14, 2025, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Jan 15, 2025, 8:00 AM EST - 1 year ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Dec 12, 2024, 12:50 PM EST - 1 year ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Dec 12, 2024, 9:00 AM EST - 1 year ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Dec 4, 2024, 8:35 AM EST - 1 year ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Nov 29, 2024, 9:55 AM EST - 1 year ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 26, 2024, 8:35 AM EST - 1 year ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Nov 22, 2024, 8:35 AM EST - 1 year ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Nov 20, 2024, 8:35 AM EST - 1 year ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Nov 11, 2024, 8:15 AM EST - 1 year ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Nov 7, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 16, 2024, 8:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aug 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Jul 1, 2024, 4:20 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Jun 28, 2024, 9:20 AM EDT - 1 year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

BLOCKS77 Apr. 6 at 7:34 PM

$APVO

0 · Reply

ProfessorDman1 Apr. 2 at 2:37 PM

$APVO 100%-500% range still active here We saw what happened to $ELAB another bio low floater 1-14 run 600%+ 🤓

0 · Reply

Habib1234 Apr. 1 at 8:21 AM

$APVO

0 · Reply

MrDaniels Apr. 1 at 7:11 AM

$APVO 👀…whatcha doin’?

0 · Reply

azazelhazel Apr. 1 at 1:22 AM

$APVO

0 · Reply

ProfessorDman1 Mar. 31 at 11:41 PM

$APVO holding full going into tomorrow

0 · Reply

alert716 Mar. 31 at 11:33 PM

$ELAB Real free daily Alerts!! 🤑🤑🤑 $APVO $MASK $GV $INDO

0 · Reply

MrDaniels Mar. 31 at 11:01 PM

$APVO wen $10?

1 · Reply

ProfessorDman1 Mar. 31 at 10:16 PM

$APVO $20+ could happen multi day

0 · Reply

Habib1234 Mar. 31 at 10:09 PM

$APVO

0 · Reply

topstockalerts Mar. 31 at 9:49 PM

$APVO it wants higher

0 · Reply

Swhite91 Mar. 31 at 8:42 PM

$APVO Just threw a bit of AH gamblin' money on this one to see if we get A.H. Squeezee

0 · Reply

ProfessorDman1 Mar. 31 at 8:38 PM

$ELAB $1.70 to near $9 we should break $10 $APVO 4 to 4.65 now should break $10 > $20+ next

0 · Reply

ProfessorDman1 Mar. 31 at 8:33 PM

$APVO won’t be surprised if this runs into $10+ tonight or tomorrow morning… $ELAB

0 · Reply

ProfessorDman1 Mar. 31 at 8:22 PM

$APVO 800K floater can go with $ELAB micro floaters both Bio

1 · Reply

ProfessorDman1 Mar. 31 at 8:16 PM

$APVO $ELAB $JAGU $LNKS $ZIVO ( your bids won’t get filled you gotta slap 👋 her ) don’t chase thou when its into double digits APVO

0 · Reply

ProfessorDman1 Mar. 31 at 8:16 PM

$APLD $APVO $ARTL $BNAI $UGRO ( your bids won’t get filled you gotta slap 👋 her ) don’t chase thou when its into double digits APVO

0 · Reply

MrDaniels Mar. 31 at 8:12 PM

Gains from $KIDZ on to $APVO 👀

0 · Reply

Habib1234 Mar. 31 at 8:11 PM

$APLD $APVO $ARTL $BNAI $UGRO

0 · Reply

MrDaniels Mar. 31 at 8:10 PM

$APVO $4.50

0 · Reply

waeng Mar. 31 at 8:09 PM

$APVO

0 · Reply

ProfessorDman1 Mar. 31 at 8:04 PM

$APVO I changed my PT $20-$40+ now from $10+ You will see soon 🔜 $4 bottomed low floater BIO with catalysts coming and BUY target $11 $ARTL $UGRO $BNAI $APLD Type of runner

0 · Reply

Market Cap	4.93M
Revenue (ttm)	0.00
Net Income (ttm)	-25.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	17,700
Avg Vol	62,228
Day's Range	N/A - N/A
Shares Out	1.18M
Stochastic %K	48%
Beta	1.50
Analysts	Sell
Price Target	$21.00